Amprion is a pioneering biotechnology company dedicated to transforming the diagnosis of neurodegenerative diseases. They specialize in the detection of misfolded proteins, such as alpha-synuclein and tau, which are key biomarkers for conditions like Parkinson's Disease, Lewy Body Dementia, and Alzheimer's Disease. Amprion's cutting-edge SYNTap® Biomarker Test, utilizing their proprietary Seed Amplification Assay (SAA) technology, offers a highly sensitive and specific method for early detection, aiding in more accurate diagnoses, patient stratification for clinical trials, and the development of new therapies. The company is committed to improving patient outcomes by providing clinicians with critical diagnostic tools.
The San Diego headquarters serves as Amprion's primary center for research and development, CLIA-certified laboratory operations, corporate administration, strategic planning, and commercialization efforts.
Features state-of-the-art laboratory facilities, including a CLIA-certified and CAP-accredited lab, specifically designed for ultrasensitive protein misfolding detection assays. Its location within a prominent San Diego biotech park provides access to a rich ecosystem of talent and collaboration.
Amprion fosters an innovative, science-driven, and collaborative work culture. Employees are mission-focused on tackling complex neurodegenerative diseases, with a strong emphasis on scientific rigor, precision, quality, and making a tangible impact on patient lives.
The headquarters' location in San Diego is highly significant, offering unparalleled access to a skilled biotech workforce, leading academic research institutions, potential industry partners, and venture capital, all crucial for Amprion's growth and innovation in the diagnostics field.
While Amprion's primary operations and laboratories are based in the United States, the company supports global initiatives through research collaborations, participation in international scientific conferences, and aims for future worldwide distribution of its diagnostic tests. Their technology is utilized in clinical studies that may involve international sites, contributing to a global understanding and approach to neurodegenerative diseases.
10030 Barnes Canyon Rd, Suite 100
San Diego
CA
USA
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, Amprion' leadership includes:
Amprion has been backed by several prominent investors over the years, including:
No major C-suite executive hires or departures have been widely publicized for Amprion in the immediate past 12 months (approx. mid-2023 to mid-2024). The leadership team appears stable, with key personnel continuing in their established roles.
Discover the tools Amprion uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Amprion commonly utilizes the email format consisting of the employee's first initial followed by their last name, preceding the '@ampriondx.com' domain. For example, an employee named Jane Doe would likely have an email address like 'jdoe@ampriondx.com'.
[first_initial][last]@ampriondx.com
Format
rlebovitz@ampriondx.com
Example
85%
Success rate
Amprion Website • May 1, 2024
Amprion announced its participation and presentation of new data on its SYNTap® alpha-synuclein seed amplification assay at the upcoming International Congress of Parkinson’s Disease and Movement Disorders®. The presentations will highlight the test's utility in detecting synucleinopathy, even in its early stages....more
PR Newswire • July 28, 2023
Amprion reported positive topline results from a pivotal clinical validation study of its SYNTap® test. The study demonstrated high accuracy in differentiating Parkinson's disease patients from healthy controls, underscoring its potential as a diagnostic aid....more
Business Wire • April 17, 2023
Amprion received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) for its SYNTap® Biomarker Test. This designation is intended to expedite the development and review of medical devices that offer more effective treatment or diagnosis of life-threatening or irreversibly debilitating diseases....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including Amprion, are just a search away.